Formulation Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Unit Size 100 µg
Storage Instructions Aliquot and store at -20°C. Minimize freezing and thawing.
Synonym / Alias Names Parkinson disease (autosomal dominant) 8\|dardarin\|leucine-rich repeat kinase 2\|DKFZp434H2111\|FLJ45829\|ROCO2\|PARK8\|LRRK2
Usage Summary Immunofluorescence: Strong expression of the protein seen in the vesicles of A431 cells and in the vesicles and nuclei of A549 cells. Recommended concentration: 10µg/ml.
Accession ID NP_940980.3
Blocking Peptide EBP06550
Immunogen Peptide with sequence CELAEKMRRTSV, from the internal region (near the C Terminus) of the protein sequence according to NP_940980.3.
Peptide Sequence CELAEKMRRTSV
Purification Method Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Shipping Instructions Refrigerated
Predicted Species Human
Reactive Species Human
Human Gene ID 120892
Product Grade
ELISA Detection Limit Antibody detection limit dilution 1:128000.
Western Blot Not yet tested - our routine western blotting protocol does not allow for the detection of proteins >250kDa (calculated MWt of approx. 286kDa according to NP_940980.3). However, customer testing has shown bands at >250kDa + 140kDa, which has been observed by other commercial sources of LRRK2 antibodies.
Application Type Pep-ELISA, IF

Selected References

[{"pmid": 19640926, "intro": "This antibody (previous batch) has been successfully used in IEM:", "title": "LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.", "author": "Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R.", "journal": "Hum Mol Genet. 2009 Nov 1;18(21):4022-34."}, {"pmid": 36219522, "intro": "This antibody has been successfully used in the following paper:", "title": "LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines.", "author": "Adrien De Guilhem De Lataillade, Martial Caillaud, Thibauld Oullier, Philippe Naveilhan, Carolina Pellegrini, Eduardo Tolosa, Michel Neunlist, Malvyne Rolli-Derkinderen, Ellen Gelpi, Pascal Derkinderen", "journal": "J Neurochem. 2023 Jan;164(2):193-209."}, {"pmid": 17971075, "intro": "This antibody (previous batch) has been successfully used in WB and IHC on Human:", "title": "LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.", "author": "Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.", "journal": "Neuropathol Appl Neurobiol. 2007 Oct 26."}, {"pmid": 21696411, "intro": "This antibody (previous batch) has been successfully used in ICC on Human:", "title": "LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study.", "author": "Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.", "journal": "Neuropathol Appl Neurobiol. 2011 Jun 23."}]

Goat Anti-LRRK2 / PARK8 (near C Terminus) Antibody

Related products